First-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer

被引：0

作者：

Sharma, Manish

Strickler, John H.

Sommerhalder, David

Kuboki, Yasutoshi

Perets, Ruth

Cohen, Jonathan

Raimbourg, Judith

Nakajima, Takako Eguchi

Yamamoto, Noboru

Cruz-Correa, Marcia

O'Neil, Bert

Ghiringhelli, Francois

Raghav, Kanwal Pratap Singh

Li, Rui

Thiele, Gladys Morrison

Aristide, Martha Raluca Neagu

Freise, Kevin Jay

de Almeida, Carla Biesdorf

Vasilopoulos, Athanasios

Powderly, John D., II

机构：

[1] START Midwest, Grand Rapids, MI USA

[2] Duke Univ, Sch Med, Durham, NC USA

[3] NEXT Oncol, San Antonio, TX USA

[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[5] Rambam Med Ctr, Haifa, Israel

[6] Technion Israel Inst Technol, Haifa, Israel

[7] Hebrew Univ Jerusalem, Sharett Inst Oncol, Wohl Inst Translat Med, Hadassah Med Ctr,Hadassh Hebrew Univ Med Ctr, Jerusalem, Israel

[8] Ctr Rene Gauducheau, Insit Cancerol Ouest, St Herblain, France

[9] Kyoto Univ, Grad Sch Med, Kyoto, Japan

[10] Natl Canc Ctr, Tokyo, Japan

[11] Univ Puerto Rico, Med Sci Campus, San Juan, PR USA

[12] Pan Amer Ctr Oncol Trials, San Juan, PR USA

[13] Community Hlth Canc Ctr North, Indianapolis, IN USA

[14] Ctr Georges Francois Leclerc, Dijon, France

[15] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[16] AbbVie Inc, N Chicago, IL USA

[17] Carolina Biooncol Inst, Huntersville, NC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3515

引用

页数：1

共 50 条

[1] Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors
Sharma, Manish
Kuboki, Yasutoshi
Camidge, D. Ross
Perets, Ruth
Sommerhalder, David
Yamamoto, Noboru
Bar, Jair
Parikh, Apurvasena
Li, Rui
Thiele, Gladys Morrison
Aristide, Martha Raluca Neagu
Freise, Kevin Jay
Powderly, John D.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] CLINICAL PHARM ACOKINETICS OF ABBV-400, A NOVEL C-MET-TARGETING ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH ADVANCED SOLID TUMORS.
Biesdorf, C.
Brunsdon, P.
Sharma, M.
Powderly, J.
Aristide, M. Neagu
Freise, K.
Menon, R.
Parikh, A.
Jennaro, T.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S63 - S63
[3] Phase 1b study evaluating the efficacy and safety of ABBV-400, a c-Met-targeting antibody-drug conjugate, in select advanced solid tumor indications.
Perets, Ruth
Sharma, Manish
Strickler, John H.
Golan, Talia
Hollebecque, Antoine
Henner, William
Vasilopoulos, Athanasios
Thiele, Gladys Morrison
Burns, Michael Charles
Harding, James J.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[4] Phase 1 study of ABBV-400, a novel anti-Met antibody drug conjugate, in advanced solid tumors
Shimizu, Toshio
Powderly, John
Sharma, Manish R.
Guan, Xiaowen
Vasilopoulos, Athanasios
Li, Martha
Li, Rui
Cunningham, Alexis
Reilly, Regina
Morrison-Thiele, Gladys
Freise, Kevin
Aristide, Martha Neagu
Camidge, D. Ross
ANNALS OF ONCOLOGY, 2023, 34 : S1397 - S1397
[5] A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer
Jin, Yangbing
Zhang, Zehui
Zou, Siyi
Li, Fanlu
Chen, Hao
Peng, Chenghong
Deng, Xiaxing
Wen, Chenlei
Shen, Baiyong
Zhan, Qian
FRONTIERS IN ONCOLOGY, 2021, 11
[6] Dose optimization and exposure-response analyses to support optimal dose of ABBV-400, a novel C-met-targeting antibody drug conjugate, in patients with metastatic colorectal cancer (mCRC).
de Almeida, Carla Biesdorf
Engelhardt, Benjamin
Babel, Heiko
Badillo, Jesus D.
Sharma, Manish
Powderly, John D., II
Aristide, Martha Raluca Neagu
Freise, Kevin Jay
Mensing, Sven
Parikh, Apurvasena
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors
Angevin, E.
Kelly, K.
Heist, R.
Morgensztern, D.
Weekes, C.
Bauer, T. M.
Ramanathan, R. K.
Nemunaitis, J.
Fan, X.
Olyaie, O.
Parikh, A.
Reilly, E.
Afar, D.
Naumovski, L.
Strickler, J.
ANNALS OF ONCOLOGY, 2016, 27
[8] First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
Demetri, George D.
Luke, Jason J.
Hollebecque, Antoine
Powderly, John D.
Spira, Alexander, I
Subbiah, Vivek
Naumovski, Louie
Chen, Chris
Fang, Hua
Lai, Dominic W.
Yue, Huibin
Polepally, Akshanth R.
Purcell, James W.
Robinson, Randy
Sharma, Padmanee
Allison, James P.
Tolcher, Anthony
Villalobos, Victor M.
CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3556 - 3566
[9] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Charlotte Lemech
Natasha Woodward
Nancy Chan
Joanne Mortimer
Louie Naumovski
Silpa Nuthalapati
Bo Tong
Fang Jiang
Peter Ansell
Christine K. Ratajczak
Jasgit Sachdev
Investigational New Drugs, 2020, 38 : 1815 - 1825
[10] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
Lemech, Charlotte
Woodward, Natasha
Chan, Nancy
Mortimer, Joanne
Naumovski, Louie
Nuthalapati, Silpa
Tong, Bo
Jiang, Fang
Ansell, Peter
Ratajczak, Christine K.
Sachdev, Jasgit
INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1815 - 1825

← 1 2 3 4 5 →